William Wing Yan Dr Lo - 27 May 2026 Form 4 Insider Report for Regencell Bioscience Holdings Ltd (RGC)

Reporting relationship: Director
Issuer ticker: RGC
Reported as of: 27 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 May 2026, 06:20:53 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ James Wai Hong Chung, attorney-in-fact

Key filing fact

William Wing Yan Dr Lo filed Form 4 for Regencell Bioscience Holdings Ltd (RGC) on 29 May 2026.

Key facts

This page summarizes William Wing Yan Dr Lo's Form 4 filing for Regencell Bioscience Holdings Ltd (RGC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 May 2026, 06:20.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001134441 Primary reporting owner

LO WILLIAM WING YAN DR

Relationship: Director
Address: C/O 9/F CHINACHEM LEIGHTON PLAZA, 29 LEIGHTON ROAD, CAUSEWAY BAY, HONG KONG, CHINA
Signature: /s/ James Wai Hong Chung, attorney-in-fact
Signature date: 29 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGC transaction Derivative

Stock option (right to purchase)

Disposed to Issuer

Transaction value
Shares: -70,600
Change %: -12%
Price
Shares after: 521,630
Date: 27 May 2026
Ownership: Direct
Underlying class: Ordinary shares, par value $0.00001
Underlying amount: 70,600
Exercise price: $0.8400
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option.

Footnote F2

On May 27, 2026, the Issuer repurchased from the Reporting Person options to purchase 70,600 ordinary shares of the Issuer at a price of $15.00 per option. The aggregate consideration payable to the Reporting Person under the Option Repurchase Agreement is further reduced by the aggregate exercise price of the repurchased options.